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Background: Since the results from the randomized TARGIT A trial were published, intraoperative radiotherapy
(IORT) is used more often. IORT can be provided as accelerated partial breast irradiation (APBI) or as a boost. The
definition of suitable patients for IORT as APBI differs between different national societies (e.g. ESTRO and ASTRO)
and different inclusion criteria of trials and so does the eligibility of patients. This analysis identifies eligible patients
for IORT according to available consensus statements and inclusion criteria of the ongoing TARGIT trials.
Methods: Between 01/03 – 12/09, 1505 breast cancer cases were treated at the breast cancer center at the
University Medical Center Mannheim. Complete data sets for age, stage (T, N, and M), histology and hormone
receptor status were available in 1108 cases. Parameters to identify eligible patients are as follows: ESTRO: >50 years,
invasive ductal carcinoma/other favorable histology (IDC), T1-2 (≤3 cm), N0, any hormone receptor status, M0;
ASTRO: ≥60 years, IDC, T1, N0, positive estrogen hormone receptor status, M0; TARGIT E “elderly”, risk adapted
radiotherapy with IORT followed by external beam radiotherapy in case of risk factors in final histopathology, phase
II: ≥70 years, IDC, T1, N0, any hormone receptor status, M0; TARGIT C “consolidation”, risk adapted radiotherapy,
phase IV: ≥50 years, IDC, T1, N0, positive hormone receptor status, M0; TARGIT BQR “boost quality registry”: every age,
every histology, T1-2 (max. 3.5 cm), any hormone receptor status, N0/+, M0/+.
Results: Out of the 1108 cases, 379 cases (34.2%) were suitable for IORT as APBI regarding the ESTRO and 175
(15.8%) regarding the ASTRO consensus statements. 82 (7.4%) patients were eligible for the TARGIT E trial, 258
(23.3%) for the TARGIT C trial and 671 (60.6%) for the TARGIT BQR registry. According to the consensus statements
of ASTRO (45.1%) and ESTRO (41.4%) about half of the eligible patients were treated with IORT as APBI. From the
eligible patients fulfilling the criteria for IORT boost (35%) about one third was eventually treated.
Conclusions: Patient selection for IORT should be restrictive. For IORT as APBI the TARGIT trials are even more
restrictive including patients than the ESTRO and ASTRO consensus statements.
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Accelerated partial breast irradiation (APBI) has been
reported having comparable local control and an excel-
lent cosmetic outcome in comparison to whole breast
radiotherapy using different techniques such as balloon
brachytherapy [1], multi-catheter technique [2], external
beam accelerated partial breast irradiation [3], intraop-
erative radiotherapy (IORT) with electrons (=IOERT)
[4,5] or with low energy x-rays (=LEX-IORT) [6,7].
LEX-IORT with 50 kV x-rays is more often used since
the results from the TARGIT A trial showed a non-
inferiority regarding local control [6,7], less toxicity, es-
pecially chronic skin toxicity [8], and an overall survival
benefit [7] for patients treated with LEX-IORT in com-
parison to patients treated with external beam radio-
therapy (EBRT). The TARGIT A trial closed recruitment
in June 2012. In the meantime the TARGIT E(lderly),
TARGIT C(onsolidation) and the TARGIT B(oost)Q
(uality)R(egistry) have been conducted or are ongoing.
The TARGIT E trial is a phase II, non-randomized
single arm trial for elderly patients above the age of
70 years (ClinicalTrials.gov Identifier: NCT01299987)
[9]. In this trial all patients receive LEX-IORT without
randomization. EBRT to the whole breast is only added
after LEX-IORT, if risk factors are present in final histo-
pathology, representing a risk adapted management as
already described for the TARGIT A trial [6]. The TAR-
GIT C trial is a phase IV, single arm trial with LEX-
IORT during breast conserving surgery for patients
above the age of 50 years and again including a risk
adapted management (EBRT in addition, if necessary).
The TARGIT C trial will start recruitment in 2014.
TARGIT BQR is a registry for patients receiving a LEX-
IORT boost (standard treatment, no experimental as-
pect, ClinicalTrials.gov Identifier: NCT01440010). Due
to quality assurance of the LEX-IORT boost, this regis-
try is ongoing since 2011 and has recruited 185 patients
in 6 centers in Germany until October 2013. While
IORT as a boost is accepted as a standard treatment in
most countries, e.g. in Germany (S3 guideline [10]),
IORT as APBI is not a standard treatment in all coun-
tries [11]. Beyond the TARGIT trials with their inclusion
and exclusion criteria, different consensus statements
exist for patient selection to provide IORT as APBI.
Consensus statements for suitable patients are available
from the ESTRO (European Society for Radiotherapy
and Oncology) [12] and ASTRO (American Society for
Radiation Oncology) [13]. The variety of statements and
inclusion criteria mark the need for a proper patient se-
lection for IORT especially as APBI. The aim of this
analysis was to estimate the eligibility of patients suit-
able for LEX-IORT as APBI (regarding the ASTRO and
ESTRO consensus statements and the inclusion criteria
from the TARGIT E and TARGIT C trial) and for LEX-IORT as a boost (regarding the inclusion criteria from
the TARGIT BQR registry).Methods
Between 01/03 – 12/09, 1505 cases were treated in the
breast cancer center of the University Medical Center
Mannheim. Primary data of all patients were collected
during six years in a database by special staff for tumor
documentation. For this analysis available data were
screened for complete parameters regarding the ASTRO
[13] and ESTRO [12] consensus statements and the in-
clusion criteria for the TARGIT E (ClinicalTrials.gov
Identifier: NCT01299987) [9] and TARGIT C trial and
the TARGIT BQR registry (ClinicalTrials.gov Identifier:
NCT01440010). Parameters to identify eligible patients
are given in detail in Figure 1. Complete data sets for
age, tumor size, nodal involvement, final histology type,
hormone receptor status and metastases were available
in 1108 cases.
Percentages were calculated for eligible patients fitting
in the predefined groups (ESTRO/ASTRO consensus
statements, TARGIT E and TARGIT C trial and TAR-
GIT BQR registry, see Figure 1). Secondly, the percent-
ages of the treated patients with IORT were calculated
to estimate the actual rate of treated patients with IORT
at a single breast cancer center regarding the ESTRO
and ASTRO consensus statements.
The TARGIT E study started recruiting patients after
the year 2009 and the TARGIT C study was in prepar-
ation at the time point of the present analysis, so no esti-
mates of treated patients within the TARGIT E and C
study could be done.
In all patients treated with LEX-IORT, a median of
20 Gy (range, 6 – 20 Gy) was delivered during breast
conserving surgery with the INTRABREAM® System
(Zeiss Meditec, Oberkochen, Germany) in a single frac-
tion during 20 – 50 minutes, depending on the applica-
tor size. Details of the method were already described
elsewhere [14]. LEX-IORT with the INTRABEAM® Sys-
tem has been used since February 2002 at the University
Medical Center Mannheim. External beam radiotherapy
with 46 – 50.4 Gy was given as a standard treatment
with 1.8 – 2.0 Gy per fraction with a dedicated linear
accelerator.Results
Eligibility for intraoperative radiotherapy as APBI
In general 928 (83.6%) out of 1108 cases were intentionally
treated with breast conserving surgery.
There were 379 (34.2%) out of 1108 cases eligible for
LEX-IORT as APBI regarding the ESTRO consensus
statements and 175 (15.8%) cases regarding the ASTRO
consensus statements. For the TARGIT E trial, 82 (7.4%)
Figure 1 Eligible patients for IORT: stratification criteria. Consensus statements: ESTRO - European Society for Radiotherapy and Oncology and
ASTRO - American Society for Radiation Oncology. Trials: TARGeted Intraoperative radioTherapy (TARGIT) E – elderly. TARGIT C – consolidation.
TARGIT BQR – boost control registry.
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gible for LEX-IORT as APBI (see Figure 2).
Eligibility for intraoperative radiotherapy as a boost
As the inclusion criteria are less restrictive for LEX-IORT
as a boost, there were 671 (60.6%) cases eligible for an
IORT boost (see Figure 2).
Actually treated patients with intraoperative radiotherapy
According to the consensus statements of ASTRO (79/
175; 45.1%) and ESTRO (157/379; 41.4%) about half of the
eligible patients were treated with IORT as APBI. From
the eligible patients fulfilling the criteria for IORT boost
(235/671; 35%) about one third was eventually treated.
Discussion
Accelerated partial breast irradiation (APBI) for early
breast cancer patients is recently used more often as there
are several techniques available, showing a good clinical
outcome and toxicity rates with usually better cosmetic
outcomes [1-8] compared to standard whole breast radio-
therapy. The present analysis was conducted to describe
eligible patients for IORT with low energy x-rays (=LEX-
IORT used as APBI or as a boost) as several consensusstatements and different inclusion criteria for studies do
co-exist with slightly different criteria. To our knowledge
no comparable assessment has been published up to now.
Therefore 1108 complete data sets of breast cancer
patients (age, tumor size, nodal involvement, final hist-
ology type, hormone receptor status and metastases)
were first analyzed regarding the eligibility of patients
for LEX-IORT as APBI in line with the ESTRO and
ASTRO consensus statements and the inclusion criteria
for the TARGIT E and C trial. Secondly, eligible patients
for LEX-IORT as a boost (TARGIT BQR registry) were
identified.
In summary, 18.5% and 34.2% of 1108 cases were eli-
gible for LEX-IORT as APBI in line with the ASTRO
and ESTRO consensus statements, respectively. For the
TARGIT E trial 7.4% and for the TARGIT C trial 23.3%
of all patients were eligible. For LEX-IORT as a boost
60.6% of all patients were eligible.
According to the consensus statements of ASTRO
(79/175; 45.1%) and ESTRO (157/379; 41.4%) about half
of the eligible patients were actually treated with IORT
as APBI. From the eligible patients fulfilling the criteria
for IORT boost (235/671; 35%) about one third was even-
tually treated. Reasons for not receiving IORT were mostly
Figure 2 Eligible patients for IORT as accelerated partial breast irradiation and for IORT as a boost. Consensus statements: ESTRO - European
Society for Radiotherapy and Oncology and ASTRO - American Society for Radiation Oncology. Trials: TARGeted Intraoperative radioTherapy (TARGIT)
E – elderly. TARGIT C – consolidation. TARGIT BQR – boost control registry. APBI – accelerated partial breast irradiation.
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partment and reasons for planned but not prescribed
IORT were already published by Tuschy et al. in 2013.
The most reported reasons for omission of a planned
IORT were an insufficient skin-tumor distance in 35.1%,
an oversized wound cavity in 24.6% and a combination
of both in 14% [15].
The range of eligible patients for LEX-IORT as APBI
ranged from 7.4% (TARGIT E trial) to 34.2% (ESTRO
consensus statements). This reflects the variety of different
definitions of suitable patients for LEX-IORT as APBI.
Having a closer look at the inclusion criteria (Figure 1),
age plays a major role in the restriction of eligible patients
as a difference of 20 years is between the ESTRO consen-
sus statements (≥50 years) and the inclusion criteria of the
TARGIT E trial (≥70 years).
Further 23.3% were eligible for the TARGIT C trial com-
pared to 34.2% eligible patients regarding the ESTRO con-
sensus statements. Indeed, the TARGIT C trial is more
restrictive in comparison to the ESTRO consensus state-
ments regarding hormone receptor status and tumor size
while both include patients above the age of 50 years. In
comparison to the ASTRO consensus statements, the
TARGIT C trial differs only as to age: ≥ 50 years (TARGIT
C) vs. ≥ 60 years (ASTRO consensus statements) leading
to close eligible patient numbers of 23.3% vs. 18.5%, re-
spectively. One may speculate on the role of age per seversus the role of menopausal status which is most likely a
biological parameter of higher relevance.
In general, the present analysis shows that patients are
highly selected for intraoperative radiotherapy especially
used as APBI. Beside patient characteristics, selection cri-
teria for APBI also reflect technical limits of the method
itself (e.g. applicator size for IORT with 50 kV/balloon
catheter, or number of possible catheters in multi-catheter
brachytherapy) or the biological and oncological rationales
of tumor treatment (e.g. subclinical tumor invasion around
the tumor bed or better prognosis of hormone receptor
positive tumors). This trend towards highly selected pa-
tients for APBI is in line with certain developments in on-
cology leading to a more and more personalized treatment
of cancer patients. For example, over the last decades mast-
ectomy is no more used for every breast cancer patient but
breast conserving surgery with adjuvant radiotherapy is
chosen as standard of care, if applicable [11]. Further, the
approach of sentinel node biopsy has replaced radical axil-
lary dissection, if applicable [10]. Additionally, personalized
systemic treatments including chemotherapy, hormone
replacement therapy and targeted therapies with e.g. anti-
bodies are available [10]. In this sense the TARGIT IORT
concept with LEX-IORT +/− EBRT is truly a personalized
and risk adapted radiotherapy.
The aim is to maximize the patients’ benefits like disease
outcome or overall survival and to minimize treatment side
Sperk et al. Radiation Oncology 2014, 9:154 Page 5 of 6
http://www.ro-journal.com/content/9/1/154effects while not deteriorating quality of life at the same
time. To achieve this aim, patient selection is essential.
How important such a strict patient selection for IORT is,
was shown by Leonardi et al. [16], where the general local
recurrence rate of 1822 included patients for IORT with
electrons as APBI was 4.1%. In the sub analyses regarding
the ESTRO consensus statements (divided into a suitable
group, cautionary group and unsuitable group for APBI)
the rates for local recurrence were 1.9% in the suitable
group, 7.4% in the cautionary group and 7.7% in the un-
suitable group (p = 0.001) [16]. The difference was even
more significant regarding the ASTRO consensus state-
ments with 1.5% in the suitable group, 4.4% in the cau-
tionary group and 8.8% in the unsuitable group (p =
0.0003) [17]. The rates of local recurrence (1.5 – 1.9%)
in the suitable groups after IORT with electrons are in
the same range as reported from the TARGIT A trial
with 1.2% [6] after LEX-IORT with 50 kV. Within the
TARGIT A trial, inclusion criteria were chosen close to
the ESTRO consensus statements and secondly a risk
adapted management including the addition of EBRT
was chosen to face risk factors in final histopathology
thus leading to low recurrence rates.
Beyond local control, toxicity and quality of life mat-
ters to the patients as mentioned before. After LEX-
IORT as APBI and also as a boost, low acute [6,18,19]
and long term side effects and especially low chronic
skin toxicities were reported [8,20,21]. In general pa-
tients with LEX-IORT as APBI were half at risk to
develop higher grade late toxicities including fibrosis,
breast edema, and edema of the arm, ulceration, hyper-
pigmentation, telangiectasia, retraction and pain [8].
After LEX-IORT as a boost, fibrosis rates are in range
with standard treatments [20,21]. Further quality of life
is significantly better in LEX-IORT patients in compari-
son to patients with whole breast radiotherapy [22,23].
Welzel et al. showed especially less breast and arm
symptoms in LEX-IORT patients during an analysis
of the TARGIT A patients in a single center [22]. In
addition the latest TARGIT A analysis [7] showed a bet-
ter overall survival in LEX-IORT patients compared to
the standard group with whole breast radiotherapy.
Vaidya et al. showed also less cardiac events and sec-
ondary cancer associated deaths in LEX-IORT patients
[7]. These results confirm the low estimated risk for sec-
ondary cancers after LEX-IORT shown by Aziz et al.
[24]. In context of cost effectiveness, attendance time or
room occupation, LEX-IORT seems to be more cost effect-
ive and needs less attendance time and room occupation
time compared to a standard external beam radiotherapy
as shown by Alvarado et al. [25] and Blank et al. [26]. In
summary, there are several good reasons from outcome
to cost effectiveness to offer intraoperative therapy to
eligible patients.Conclusions
This analysis shows that patient selection for intraopera-
tive radiotherapy is restrictive, especially for IORT as
APBI, and that the TARGIT trials are even more restrict-
ive considering patients for LEX-IORT than the ESTRO
and ASTRO consensus statements.
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